

# Will people change their vector-control practices in the presence of an imperfect dengue vaccine?

T. M. Q. R. BOCCIA<sup>1</sup>, M. N. BURATTINI<sup>1</sup>, F. A. B. COUTINHO<sup>1</sup>  
AND E. MASSAD<sup>1,2\*</sup>

<sup>1</sup>School of Medicine, The University of São Paulo, São Paulo, SP, Brazil and LIM01 HC-FMUSP

<sup>2</sup>London School of Hygiene and Tropical Medicine, London University, London, UK

Received 6 February 2013; Final revision 2 April 2013; Accepted 6 May 2013;  
first published online 5 June 2013

## SUMMARY

Human behaviours, which are influenced by social, cultural, economic and political factors, can increase or decrease the risk of dengue infection, depending on the relationship with the insect vector. Because no vaccine is currently available, the spread of dengue can only be curtailed by controlling vector populations (*Aedes aegypti* and others) and by protecting individuals. This study tested the hypothesis that dengue-affected populations are likely to relax their vector-control habits if a potentially protective vaccine becomes available. The hypothesis was tested using two approaches: a mathematical model designed to describe dengue transmission and an empirical field test in which the local population of an endemic area was interviewed about their vector-control habits given the presence of a theoretical vaccine. The model demonstrated that depending on the level of vector-control reduction, there is a threshold in vaccine efficacy below which it is better not to introduce the vaccine. The interview showed that people who were informed that a very effective vaccine is available would reduce their vector-control habits significantly compared to a group that was informed that the vaccine is not very effective.

**Key words:** Dengue fever, epidemiology, health policy, infectious disease control, vaccines.

## INTRODUCTION

Dengue is a viral mosquito-borne infection, which in recent years has become a major international public health concern because it is a leading cause of illness and death in the tropics and subtropics [1–3]. It is estimated that there are 70–500 million dengue infections, 36 million cases of dengue fever (DF), 2·1 million cases of dengue haemorrhagic fever (DHF), and more than 20 000 dengue-related deaths every year [3].

Due to increased epidemic activity and difficulties in controlling the insect vector, dengue has become

a major public health problem in many parts of the tropics [4]. Human behaviours, which are influenced by social, cultural, economic and political factors [5], can increase or decrease the risk of dengue infection, depending on the relationship with the insect vector. Because no vaccine is currently available, the spread of dengue can be curtailed only by controlling vector populations (*Aedes aegypti* and others) and by protecting individuals. *Aedes* larvae are the main target for vector control efforts; their populations can be reduced by using biological agents, including larvivorous fish (e.g. *Poecilia reticulata*, *Gambusia affinis*) and copepods (e.g. *Mesocyclops*) [6], larvicides (e.g. *Bacillus thuringiensis* subsp. *israelensis*, methoprene, permethrin, and temephos) and by removing water containers. Environmental management is generally

\* Author for correspondence: Dr E. Massad, School of Medicine, The University of São Paulo, Av. Dr Arnaldo 455, São Paulo, CEP 01246-903, SP, Brazil and LIM01 HC-FMUSP. (Email: edmassad@usp.br)

considered an important component of dengue prevention and control.

During the past few decades, efforts to promote community-oriented activities for dengue control have increased. These have included multi-component interventions to reduce larval, and ultimately adult, vector populations through chemical, biological and physical interventions, as well as promoting behavioural change at the community level.

The advent of several candidate tetravalent vaccines against the dengue viruses gives hope of controlling and eventually eliminating the disease [7]. The efficacy of the potential vaccines, however, is likely to be much less than 100% [8]. This raises the concern that people might reduce their vector-control practices if they believe that the vaccine is affording them full protection. It should be expected that with a vaccine available, vector-control practices such as finding and destroying mosquito breeding sites, will be perceived as requiring too much effort. Hence, if a vaccine's efficacy is not sufficient, then its introduction may increase the spread of the disease. This apparent paradox has already been observed in the case of the introduction of antiretroviral therapies against HIV, which provided incomplete protection but led to a reduction of safe behaviour [9]. This situation was modelled by Massad *et al.* [10]. An earlier hepatitis B vaccine trial involving homosexual and bisexual men provided indirect evidence that men increased their participation in risky behaviours. Indeed, infection rates in the placebo group increased after participants received all of their injections. This finding suggests that the study participants actually waited for this point and then engaged in more risky behaviours, believing that they were protected, even though they knew that they were in a placebo-controlled trial [11].

This study aimed to test the hypothesis that dengue-affected populations will reduce their vector-control practices if a potentially protective vaccine becomes available. The hypothesis was tested using two approaches: a mathematical model designed to describe dengue transmission and an empirical field test in which the local population of an endemic area was interviewed about their vector-control habits given the presence of a theoretical vaccine.

**METHODS**

**The model**

The model's dynamics were modified from a version of the model described previously [12–14]. The

structure, including the number of compartments, transition rates, etc., is the same as the models presented previously [12–14].

The populations involved in transmission are human hosts, mosquitoes, and their eggs (including intermediate stages, such as larvae and pupae). The population densities, therefore, were divided into the following compartments: susceptible humans,  $S_H$ ; infected humans,  $I_H$ ; recovered (and immune) humans,  $R_H$ ; total humans,  $N_H$ ; susceptible mosquitoes,  $S_M$ ; infected and latent mosquitoes,  $L_M$ ; infected and infectious mosquitoes,  $I_M$ ; non-infected eggs,  $S_E$ ; and infected eggs,  $I_E$ .

The model's equations are:

$$\left. \begin{aligned}
 \frac{dS_H}{dt} &= abI_M \frac{S_H}{N_H} - \mu_H S_H + r_H N_H \left(1 - \frac{N_H}{\kappa_H}\right) - v\phi S_H \\
 \frac{dI_H}{dt} &= abI_M \frac{S_H}{N_H} - (\mu_H + \alpha_H + \gamma_H) I_H \\
 \frac{dR_H}{dt} &= \gamma_H I_H - \mu_H R_H + v\phi S_H \\
 \frac{dS_M}{dt} &= p_s c_s(t) S_E - \mu_M S_M - ac S_M \frac{I_H}{N_H} \\
 \frac{dL_M}{dt} &= ac S_M \frac{I_H}{N_H} - e^{-\mu_M \tau_1} ac S_M(t - \tau_1) \frac{I_H(t - \tau_1)}{N_H(t - \tau_1)} \\
 &\quad - \mu_M L_M \\
 \frac{dI_M}{dt} &= e^{-\mu_M \tau_1} ac S_M(t - \tau_1) \frac{I_H(t - \tau_1)}{N_H(t - \tau_1)} \\
 &\quad - \mu_M I_M + p_I c_S(t) I_E \\
 \frac{dS_E}{dt} &= [r_M S_M + (1 - g)r_M I_M] \left(1 - \frac{(S_E + I_E)}{\kappa_E}\right) \\
 &\quad - \mu_E S_E - p_S c_S(t) S_E \\
 \frac{dI_E}{dt} &= [g r_M I_M] \left(1 - \frac{(S_E + I_E)}{\kappa_E}\right) - \mu_E I_E - p_I c_S(t) I_E
 \end{aligned} \right\} \tag{1}$$

where  $c_S(t) = (d_1 - d_2 \sin(2\pi ft + \phi))$  is a climatic factor mimicking seasonal influences on the mosquito population (see below and references [12–14]). The parameters are defined in Table 1.

Note that the parameters  $v$  and  $\phi$  always occur together, therefore it would seem more correct to represent them as a single parameter. However, in order to provide generality for the model and flexibility to the simulations we decided to represent them separately. Hence, when we vary the vaccine efficacy in the simulations, we vary only the value of  $\phi$ , keeping the vaccination rate  $v$  constant.

An important assumption related to vector-control habits is that reducing the time-dependent intensity of breeding-site elimination will result in an

Table 1. The notation, biological meaning and values of parameters applied in the simulations. Values are derived from [12]

Parameter	Meaning	Value
$a$	Average daily biting rate	0.164*
$b$	Fraction of bites actually infective to humans	0.6
$\mu_H$	Natural mortality rate of humans	$3.5 \times 10^{-5}$ days <sup>-1</sup>
$r_H$	Birth rate of humans	$2.4 \times 10^{-5}$ days <sup>-1</sup>
$\kappa_H$	Carrying capacity of humans	$4 \times 10^5$
$\alpha_H$	Dengue mortality in humans	$10^{-3}$ days <sup>-1</sup>
$\gamma_H$	Recovery rate of humans	0.143 days <sup>-1</sup>
$P_S$	Hatching rate of susceptible eggs	0.15 days <sup>-1</sup>
$d_1$	Winter modulation parameter	0.07
$d_2$	Winter modulation parameter	0.06
$f$	Frequency of seasonal cycles	$2.8 \times 10^{-3}$ days <sup>-1</sup>
$\mu_M$	Natural mortality rate of mosquitoes	0.09 days <sup>-1</sup>
$\tau$	Extrinsic incubation period	7 days
$\alpha_M$	Dengue mortality in mosquitoes	Negligible
$r_M$	Oviposition rate	50 days <sup>-1</sup>
$P_I$	Hatching rate of infected eggs	
$g$	Proportion of infected eggs	0.5
$\kappa_E$	Carrying capacity of eggs	$98 \times 10^6$
$\varepsilon$	Parameter in equation (2)	60 days <sup>-1</sup>
$\mu_E$	Natural mortality rate of eggs	0.1 days <sup>-1</sup>
$c$	Fraction of bites actually infective to mosquitoes	0.54
$v$	Vaccination rate	0.06 days <sup>-1</sup>
$\varphi$	Vaccine efficacy	Variable
$\Omega$	Term of increase in $\kappa_E$	Variable

\* From [15].

improvement in the breeding conditions of *Aedes* mosquitoes, which can be simulated by a linear increase in the aquatic forms' carrying capacity,  $\kappa_E$ , such that:

$$\kappa_E(t) = \kappa_E(0) + \varepsilon t, \quad (2)$$

that is,  $\kappa_E$  increases linearly at a rate  $\varepsilon$  with time until  $t = t'$ . If the affected population has a given intensity of breeding-site elimination of *Aedes* mosquitoes until time  $t < t'$  before the vaccine, and this is reduced after the vaccine, then the carrying capacity will increase by an additional constant  $\Omega$  to the rate  $\varepsilon$ , and equation (2) reads as:

$$\kappa_E(t) = \kappa_E(0) + [\varepsilon + \Omega\theta(t - t')]t, \quad (3)$$

The term  $\theta(t - t')$  is the Heaviside step function that is zero for  $t < t'$  and 1 for  $t \geq t'$ .

### Empirical test of the hypothesis

#### Source population

The source population was comprised of patients and their relatives or acquaintances in the waiting room of the outpatient service of the Clinic's Hospital of the

School of Medicine of the University of São Paulo, Brazil. This outpatient service receives more than one million patients per year from all parts of the country, and most of these patients are accompanied by a relative or an acquaintance. They can, therefore, be considered as a good representation of the general population.

#### Sampling method


The sample sizes of the two groups investigated (details below) were calculated using the method described by [16] for comparative studies. To calculate the sample size for a study that compares two groups, the following information is required:

- The expected population proportion in group 1,  $P_1$ ,
- The expected population proportion in group 2,  $P_2$ ,
- The significance level  $\alpha$ .
- The power of the test  $(1 - \beta)$ .

The number of individuals in each group is:

$$n = \frac{k[P_1(1 - P_1) + P_2(1 - P_2)]}{(P_1 - P_2)^2},$$





**Fig. 1** [colour online]. Results of the numerical simulation of system (1) with six projected scenarios related to the probability of relaxing vector-control measures, from 10% to 50%. The figure shows the force of infection as a function of the vaccine efficacy. The dotted line represents the force of infection in the absence of vaccination.

test of normality. This test result rejected the normality hypothesis and hence the variable ‘total score’ for items related to vector-control habits was compared between the two groups using a Mann–Whitney test for independent analysis.

## RESULTS

### Model simulation

Figure 1 shows the result of the numerical simulation of system (1) with six projected scenarios related to the probability of relaxing vector-control measures, from 10% to 50%. The figure shows the force of infection as a function of vaccine efficacy. It should be noted that at baseline, a vaccine with ~40% efficacy is sufficient to eradicate the infection. When the probability of relaxing vector-control measures is 10%, the vaccine efficacy necessary to bring the force of infection down to zero is ~50%, and so on. In the worst scenario simulated, the probability of relaxing vector-control measures is 50% and the eradication is >80%. Hence, for the latter scenario, unless the vaccine efficacy is >0.5%, the introduction of the vaccine worsens the epidemic (the force of infection is greater than the baseline situation, i.e. 0% probability of relaxing vector control measures).

Note that in the baseline scenario (i.e. 0% probability of relaxing vector control measures) any vaccine with efficacy >40% is enough to eradicate the disease (provided, of course that 100% of the target population is vaccinated). This is compatible with the relatively low value of  $R_0$  (in this case, around 1.7).


Another way to see this phenomenon is shown in Figure 2, in which a simulation of system (1) is shown for the dengue situation in Singapore. The vaccine is introduced by week 180, and the population is assumed to reduce vector control by 45%. In this case, it can be observed that unless the vaccine efficacy is >75%, it is better not to introduce the vaccine because the number of cases with the less efficacious vaccine is greater than that in the absence of vaccination.

### Interviews

In both groups, the variable ‘total score’ showed a non-normal distribution by the Kolmogorov–Smirnov test. The average scores were 5.72 (s.e.=0.16) for the group that was informed of a high-efficacy vaccine and 6.22 (s.e.=0.12) for the group that was informed of a low-efficacy vaccine. This difference was statistically significant [Mann–Whitney  $U$  ( $n_1=100$ ;  $n_2=100$ )=3350.5,  $P=3.2 \times 10^{-6}$ , one-tailed,  $d=0.67$ ], although the size effect (Cohen’s  $d$ ) was not too great. This finding suggests that there is a trend in the direction of vector-control habit relaxation, such that the more people feel protected by the vaccine the less the total score, i.e. the less people care about measures related to mosquito control.

## DISCUSSION

No medical intervention has such an unambiguous record of preventing morbidity and mortality from infectious diseases than that of vaccines [17]. However, there is no vaccine that is absolutely safe with



**Fig. 2** [colour online]. Simulation of system (1) for the dengue situation in Singapore. The vaccine is introduced by week 180 and the population is assumed to reduce vector control by 45%. In the simulation, the carrying capacity for the aquatic phases increases according to equation (3). The situation labelled 'no control' means the natural course of the epidemic without vaccination.

no side-effects. Some vaccines are relatively safe, with only minor side-effects, such as low fever and a discrete cutaneous rash. Other vaccines, such as the rubella vaccine, can cause grave and undesirable effects when the age of the target population or the minimum proportion vaccinated are not optimized [18]. In some cases, serious adverse effects, including death, can reach unacceptable levels, as occurred during the recent yellow fever outbreak in São Paulo, Brazil, in which there was 1 death/200 000 doses of live-attenuated yellow fever vaccine (described in [19]).

The candidate dengue vaccines tested so far have been demonstrated to be safe [20] regarding adverse effects primarily caused by the vaccine itself, such as mild symptoms of headache, malaise, and eye pain. In some cases, those who received the vaccine noted more moderate symptoms with onset from study days 8–11 and developed maculopapular rashes distributed over the trunk and extremities. Transient neutropenia (white blood cells  $<4000 \text{ mm}^3$ ), but not thrombocytopenia (platelets  $<100\,000 \text{ mm}^3$ ), were noted after vaccination [21]. Hence, live-attenuated dengue virus vaccines are safe and tolerable in humans and their mild-to-moderate side-effects should not cause too much concern. However, the efficacy demonstrated by the most advanced dengue vaccine candidate in a recent phase 2b trial in Thailand [22] was 30.2% (95% confidence interval 13.4–56.6), and differed by serotype. Although still preliminary and very much dependent on larger trials, these results demonstrate that the likely dengue vaccine will not be (and should not be expected to be) 100% efficacious. The high expectations of the affected popu-

lations of a vaccine as the only hope to eliminate dengue, however, are worrisome. The false feeling of perfect protection may cause the population to reduce costly vector-control measures. Thus, depending on the intensity of behavioural change by the affected population, unless the vaccine has a minimum efficacy, its introduction may increase the intensity of transmission.

The results of the questionnaire strongly suggest that the population will relax vector-control measures, and this relaxation may result in a significant increase in dengue transmission, as shown by the model. These results support the proposed hypothesis.

The present study has some important limitations, such as the oversimplified structure of the proposed model and the small sample interviewed, but our approach was not intended to be comprehensive. Rather, this study aimed to raise the hypothesis about changing vector-control behaviour in the presence of a dengue vaccine and to test it in two different ways. In addition, the conclusions presented hold only when people's behavioural change (for worse) in the initial period after the introduction of the vaccine is not modified with time. However, it is likely that this 'static' behavioural scenario might not be observed. Indeed, it is expected that people's perception will rapidly change when it becomes clear that the vaccine is not working as expected during the course of an epidemic, and their behaviour will revert to their original practices. In a future work we will expand the questionnaire to accommodate the possibility of changing one's behaviour under such a dynamic scenario. We are planning a more extensive study in which

a larger sample will be interviewed, to provide increased statistical power to verify the preliminary results we found in the current study.

## ACKNOWLEDGEMENTS

This research received funding from the European Union's Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 282589 from LIM01 HCFMUSP and CNPq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## DECLARATION OF INTEREST

None.

## REFERENCES

1. **Gubler DJ.** Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. *Trends in Microbiology* 2002; **10**: 100–103.
2. **Wilder-Smith A, Gubler DJ.** Geographic expansion of dengue: the impact of international travel. *Medical Clinics of North America* 2008; **92**: 1377–1390.
3. **Wilder-Smith A, et al.** Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. *Current Infectious Diseases Report* 2010; **12**: 157–164.
4. **Heintz C, Velasco Garrido M, Kroeger A.** What do community-based dengue control programmes achieve? A systematic review of published evaluations. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2007; **101**: 317–325.
5. **Heggenhougen K, Hacketh V, Vivek P.** The behavioural and social aspects of malaria and its control. WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, 2003, TDR/STR/SEB/VOL/031.
6. **Kay BH, et al.** Control of *Aedes* vectors of dengue in three provinces of Vietnam by use of *Mesocyclops* (Copepoda) and community-based methods validated by entomologic, clinical, and serological surveillance. *American Journal of Tropical Medicine and Hygiene* 2002; **66**: 40–48.
7. **Chao DL, et al.** Controlling dengue with vaccines in Thailand. *PLoS Neglected Tropical Diseases* 2012; **6**: e1876.
8. **Amaku M, Coudeville L, Massad E.** Designing a vaccination strategy against dengue. *Revista do Instituto de Medicina Tropical de Sao Paulo* **54** (Suppl. 18): S18–S21.
9. **Perez Gonzalez K, Domingo SA, Hartnoll R.** Prevalence of human immunodeficiency virus and risk behaviours among opioid users in an emergency room. *Gaelic Sanitatis* 1999; **13**: 7–15.
10. **Massad E, et al.** Modeling the impact of imperfect HIV vaccines on the incidence of the infection. *Mathematical and Computer Modelling* 2001; **34**: 345–351.
11. **Buchbinder S.** (1999) Studying the volunteers who make HIV vaccine trials possible, *IAVI Report* **4**: 9.
12. **Burattini MN, et al.** Modelling the control strategies against dengue in Singapore. *Epidemiology and Infection* 2008; **136**: 309–319.
13. **Coutinho FAB, et al.** Threshold conditions for a non-autonomous epidemic system describing the population dynamics of dengue. *Bulletin of Mathematical Biology* 2006; **68**: 2263–2282.
14. **Lopez LF, et al.** Threshold conditions for infection persistence in complex host-vector interactions. *Comptes Rendus Biologies* 2002; **325**: 1073–1084.
15. **Yasuno M, Tonn RJ.** A study of biting habits of *Aedes aegypti* in Bangkok, Thailand. *Bulletin of the World Health Organization* 1970; **43**: 319–325.
16. **Bland M.** *An Introduction to Medical Statistics*, 3rd edn. Oxford: Oxford University Press, 2000.
17. **Massad E, Burattini MN, Ortega NRS.** Fuzzy logic and measles vaccination: designing a control strategy. *International Journal of Epidemiology* 1999; **28**: 550–557.
18. **Azevedo Neto RS, et al.** (1994). Rubella seroepidemiology in a non-immunized population of São Paulo State, Brazil. *Epidemiology and Infections* **113**: 161–173.
19. **Moreno ES and the Yellow Fever Working Group.** Reemergence of yellow fever: detection of transmission in the state of São Paulo, Brazil. *Revista da Sociedade Brasileira de Medicina Tropical* 2011; **44**: 290–296.
20. **Leo YS, et al.** Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 y. Phase II randomized controlled trial in Singapore. *Human Vaccines & Immunotherapeutics* 2012; **8**: 1259–1271.
21. **Kanesa-thasan N, et al.** Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. *Vaccine* 2001; **19**: 3179–3188.
22. **Sabchareon A, et al.** Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. *Lancet* 2012; **380**: 1559–1567.

## APPENDIX

## Questionnaire used for estimating the sample's vector-control habits and knowledge about dengue transmission and prevention

Number:	Questionnaire about dengue	__/__/__
---------	----------------------------	----------

Age	Sex	Postal code	Profession	Education level*

\*Table below

(1) Incomplete first degree	(4) Incomplete second degree	(6) Incomplete college
(2) Complete first degree	(5) complete second degree	(7) Complete college

Instructions for coding the answers:

(1) Fully disagree	(3) Indifferent	(4) Agree
(2) Disagree		(5) Fully agree

	(1)	(2)	(3)	(4)	(5)
I know what dengue is and how it is transmitted					
The mosquito <i>A. aegypti</i> is the disease's vector					
I can catch dengue by direct contact with a diseased person					
I can catch dengue by drinking contaminated water					
I can only catch dengue when bitten by <i>A. aegypti</i>					
I can influence dengue transmission through my actions/attitudes					
The dengue mosquito breeds in dirty water					
The dengue mosquito breeds in clean water					
Plant vases, old tyres, bottles, and bottle caps can be breeding places for the dengue mosquito					
Water reservoirs that are incompletely covered can be breeding places for the dengue mosquito					
Accumulated water in roof gutters can be a breeding place for the dengue mosquito					
I ought to contribute to dengue control by removing the breeding places in and around my house					
I ought to contribute to dengue control by informing my neighbours about what has to be done					
Putting sand in plant vases helps to control dengue					
Keeping water reservoirs clean and well-lit helps to control dengue					
Removing trash and old tyres does not help dengue control					
Cleaning the roof gutters helps to control dengue					
I ought to contribute to dengue control by alerting the health authorities about problems in my borough					
I have to wait until the health authorities visit my house to eliminate <i>A. aegypti</i> breeding sites					
I always remove all of the water from plant vases, putting sand in its place					
I always remove objects that accumulate water from the backyard of my house					
I always keep the water reservoirs well cleaned					
I always keep the water reservoirs well lit					
I always alert my neighbours about what has to be done for controlling dengue					
I do not wait until the health authorities visit my house to eliminate <i>A. aegypti</i> breeding sites					
I believe that the vaccine will eliminate dengue					
Only children should be vaccinated					
I would like to be vaccinated					
If I were vaccinated, then I would not need to remove water from the plant vase or to put sand in its place					

If I were vaccinated, then I would not need to worry about properly covering the water reservoir					
If I were vaccinated, then I would not need to care about the trash in my backyard					
If I were vaccinated, then I would not need to care about cleaning the roof gutters					
If I were vaccinated, then I would never catch dengue					
If I were vaccinated, then I would not need to care about talking about dengue with my neighbours					
I will be one of the first to be vaccinated					
I do not believe that the vaccine can eliminate dengue					